Comparative rates of upstaging and upgrading in Caucasian and Korean prostate cancer patients eligible for active surveillance
- PMID: 29136019
- PMCID: PMC5685613
- DOI: 10.1371/journal.pone.0186026
Comparative rates of upstaging and upgrading in Caucasian and Korean prostate cancer patients eligible for active surveillance
Abstract
Purpose: To investigate the impact of race on the risk of pathological upgrading and upstaging at radical prostatectomy (RP) in an Asian (Korean) and Western (Caucasian) cohort eligible for active surveillance (AS).
Materials and methods: We performed a retrospective cohort study of 854 patients eligible for AS who underwent RP in United States (n = 261) and Korea (n = 593) between 2006 and 2015. After adjusting for age, PSA level, and prostate volume, we utilized multivariate logistic regression analysis to assess the effect of race on upgrading or upstaging.
Results: There were significant differences between Caucasian and Korean patients in terms of age at surgery (60.2 yr. vs. 64.1 yr.), PSA density (0.115 ng/mL/mL vs. 0.165 ng/mL/mL) and mean number of positive cores (3.5 vs. 2.4), but not in preoperative PSA values (5.11 ng/mL vs. 5.05 ng/mL). The rate of upstaging from cT1 or cT2 to pT3 or higher was not significantly different between the two cohorts (8.8% vs. 11.0%, P = 0.341). However, there were higher rates of upgrading to high-grade cancer (Gleason 4+3 or higher) in Korean patients (9.1%) when compared to Caucasian counterparts (2.7%) (P = 0.003). Multivariate logistic regression analysis showed that age (OR 1.07, P < 0.001) and smaller prostate volume (OR 0.97, P < 0.001), but not race, were significantly associated with upstaging or upgrading.
Conclusions: There were no differences in rates of upgrading or upstaging between Caucasian and Korean men eligible for active surveillance.
Conflict of interest statement
Similar articles
-
Racial variation in prostate cancer upgrading and upstaging among men with low-risk clinical characteristics.Eur Urol. 2015 Mar;67(3):451-7. doi: 10.1016/j.eururo.2014.03.026. Epub 2014 Apr 5. Eur Urol. 2015. PMID: 24746973
-
The impact of race/ethnicity on upstaging and/or upgrading rates among intermediate risk prostate cancer patients treated with radical prostatectomy.World J Urol. 2022 Jan;40(1):103-110. doi: 10.1007/s00345-021-03816-0. Epub 2021 Aug 26. World J Urol. 2022. PMID: 34436637
-
No detrimental effect of a positive family history on postoperative upgrading and upstaging in men with low risk and favourable intermediate-risk prostate cancer: implications for active surveillance.World J Urol. 2021 Jul;39(7):2499-2506. doi: 10.1007/s00345-020-03485-5. Epub 2020 Oct 13. World J Urol. 2021. PMID: 33048258 Free PMC article.
-
Heterogeneity in D'Amico classification-based low-risk prostate cancer: Differences in upgrading and upstaging according to active surveillance eligibility.Urol Oncol. 2015 Jul;33(7):329.e13-9. doi: 10.1016/j.urolonc.2015.04.004. Epub 2015 May 7. Urol Oncol. 2015. PMID: 25960411
-
Pathologic Outcomes of Gleason 6 Favorable Intermediate-Risk Prostate Cancer Treated With Radical Prostatectomy: Implications for Active Surveillance.Clin Genitourin Cancer. 2018 Jun;16(3):226-234. doi: 10.1016/j.clgc.2017.10.013. Epub 2017 Nov 9. Clin Genitourin Cancer. 2018. PMID: 29196209
Cited by
-
Old men with prostate cancer have higher risk of Gleason score upgrading and pathological upstaging after initial diagnosis: a systematic review and meta-analysis.World J Surg Oncol. 2021 Jan 20;19(1):18. doi: 10.1186/s12957-021-02127-3. World J Surg Oncol. 2021. PMID: 33472645 Free PMC article.
References
-
- Cooperberg MR, Carroll PR. Trends in Management for Patients With Localized Prostate Cancer, 1990–2013. Jama. 2015;314(1):80–2. doi: 10.1001/jama.2015.6036 . - DOI - PubMed
-
- Huland H, Graefen M. Changing Trends in Surgical Management of Prostate Cancer: The End of Overtreatment? European urology. 2015;68(2):175–8. doi: 10.1016/j.eururo.2015.02.020 . - DOI - PubMed
-
- Klotz L, Zhang L, Lam A, Nam R, Mamedov A, Loblaw A. Clinical results of long-term follow-up of a large, active surveillance cohort with localized prostate cancer. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2010;28(1):126–31. doi: 10.1200/JCO.2009.24.2180 . - DOI - PubMed
-
- Tosoian JJ, Trock BJ, Landis P, Feng Z, Epstein JI, Partin AW, et al. Active surveillance program for prostate cancer: an update of the Johns Hopkins experience. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2011;29(16):2185–90. doi: 10.1200/JCO.2010.32.8112 . - DOI - PubMed
-
- Newcomb LF, Thompson IM Jr., Boyer HD, Brooks JD, Carroll PR, Cooperberg MR, et al. Outcomes of Active Surveillance for Clinically Localized Prostate Cancer in the Prospective, Multi-Institutional Canary PASS Cohort. The Journal of urology. 2016;195(2):313–20. doi: 10.1016/j.juro.2015.08.087 . - DOI - PMC - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous